For laboratory research use only. Not for human consumption.
Talk to our research support team: 512-998-2437
For laboratory research use only. Not for human consumption.
Talk to our research support team: 512-998-2437
Price range: $66.50 through $630.00
These products are for laboratory research only and not intended for medical use. They are not FDA-approved to diagnose, treat, cure, or prevent any disease. By purchasing, you certify they will be used solely for research and not for human or animal consumption.
Research Use Only
All research peptides supplied by OPTMZ Peptides are intended strictly for laboratory research applications and are not designed for medical use. These materials are not approved by the U.S. Food and Drug Administration (FDA) to diagnose, treat, cure, or prevent any disease. By purchasing, the buyer confirms use strictly for scientific research purposes and not for human or animal consumption.
Product Overview
CJC-1295 (with DAC) is a synthetic analog of growth hormone-releasing hormone (GHRH) engineered with a Drug Affinity Complex (DAC) designed to interact with circulating albumin and extend the peptide’s biological persistence.
Experimental research has examined CJC-1295 in GHRH receptor signaling, growth hormone and IGF-1 axis research, albumin-binding pharmacology, pituitary signaling, and endocrine physiology. Published work describes CJC-1295 as a long-acting GHRH analog with markedly extended pharmacokinetic activity compared with native GHRH.
The purity, identity, measured content, and CAS number above come directly from the Krause Analytical report for the submitted OPTMZ sample.
For the fully DAC-modified CJC-1295 molecule, PubChem reports molecular formula C₁₆₅H₂₆₉N₄₇O₄₆ and molecular weight 3647.2 g/mol.
Each tested batch of CJC-1295 (with DAC) undergoes analytical evaluation to verify chromatographic purity, identity, peptide content, and analytical consistency.
For the submitted OPTMZ Peptides sample, independent testing by Krause Analytical reported:
The laboratory states that the data presented are from the analyzed sample and meet internal quality-assurance criteria unless otherwise flagged.
The second page of the COA includes the chromatogram and a direct comparison between the sample mass spectrum and the CJC-1295 DAC reference spectrum.
Note: This COA does not report endotoxin testing, so I would not state that this specific lot was endotoxin tested.
CJC-1295 (with DAC) should be handled by qualified professionals in controlled laboratory environments. Appropriate storage conditions should be maintained to preserve peptide stability and structural integrity.
Avoid unnecessary exposure to heat, moisture, light, and repeated temperature fluctuations. Experimental preparation, storage, and handling should follow validated laboratory procedures appropriate to the intended research application.
CJC-1295 (with DAC) has been investigated in experimental and clinical research involving the GHRH/GH/IGF-1 signaling axis and long-acting peptide pharmacology.
Research areas include:
CJC-1295 was developed as a modified hGRF(1-29) analog capable of covalent albumin association, thereby extending its plasma persistence. Experimental work identified it as a stable and active hGRF analog with an extended half-life.
Human research has also examined its pharmacokinetics and effects on circulating GH and IGF-1 in controlled studies.
These research findings do not establish that the product supplied here is approved for therapeutic use.
CJC-1295 (with DAC) continues to be evaluated as an experimental tool for studying GHRH receptor signaling, pituitary endocrine biology, GH/IGF-1 pathway regulation, albumin-binding peptide design, and extended-duration peptide pharmacology.
The DAC modification is particularly relevant to laboratory investigations of peptide bioconjugation because CJC-1295 is designed to associate with endogenous albumin, extending biological persistence compared with unmodified GHRH analogs.
For laboratory research use only. Intended strictly for in vitro and controlled experimental research applications.
All products currently listed on this site are for research purposes ONLY.
The purity, identity, measured content, and CAS number above come directly from the Krause Analytical report for the submitted OPTMZ sample.
For the fully DAC-modified CJC-1295 molecule, PubChem reports molecular formula C₁₆₅H₂₆₉N₄₇O₄₆ and molecular weight 3647.2 g/mol.
Each tested batch of CJC-1295 (with DAC) undergoes analytical evaluation to verify chromatographic purity, identity, peptide content, and analytical consistency.
For the submitted OPTMZ Peptides sample, independent testing by Krause Analytical reported:
The laboratory states that the data presented are from the analyzed sample and meet internal quality-assurance criteria unless otherwise flagged.
The second page of the COA includes the chromatogram and a direct comparison between the sample mass spectrum and the CJC-1295 DAC reference spectrum.
Note: This COA does not report endotoxin testing, so I would not state that this specific lot was endotoxin tested.
CJC-1295 (with DAC) should be handled by qualified professionals in controlled laboratory environments. Appropriate storage conditions should be maintained to preserve peptide stability and structural integrity.
Avoid unnecessary exposure to heat, moisture, light, and repeated temperature fluctuations. Experimental preparation, storage, and handling should follow validated laboratory procedures appropriate to the intended research application.
CJC-1295 (with DAC) has been investigated in experimental and clinical research involving the GHRH/GH/IGF-1 signaling axis and long-acting peptide pharmacology.
Research areas include:
CJC-1295 was developed as a modified hGRF(1-29) analog capable of covalent albumin association, thereby extending its plasma persistence. Experimental work identified it as a stable and active hGRF analog with an extended half-life.
Human research has also examined its pharmacokinetics and effects on circulating GH and IGF-1 in controlled studies.
These research findings do not establish that the product supplied here is approved for therapeutic use.
CJC-1295 (with DAC) continues to be evaluated as an experimental tool for studying GHRH receptor signaling, pituitary endocrine biology, GH/IGF-1 pathway regulation, albumin-binding peptide design, and extended-duration peptide pharmacology.
The DAC modification is particularly relevant to laboratory investigations of peptide bioconjugation because CJC-1295 is designed to associate with endogenous albumin, extending biological persistence compared with unmodified GHRH analogs.
For laboratory research use only. Intended strictly for in vitro and controlled experimental research applications.
All products currently listed on this site are for research purposes ONLY.
| Pcs | Single Vial, Pack of 10 |
|---|---|
| Strength | 5mg |
Long-Acting GHRH Analog / Growth Hormone-Releasing Hormone Research Peptide
Endocrinology; Peptide Biology; GHRH/GH/IGF-1 Axis Research; Pharmacology; Peptide Bioconjugation; Pituitary Biology
Growth Hormone-Releasing Hormone Receptor (GHRHR) Secondary structural interaction: Serum albumin via the DAC maleimide functionality Published research describes CJC-1295 as a GHRH analog that activates the GHRH receptor while its DAC moiety enables covalent albumin association.
Clinical Research Unlike many research peptides, CJC-1295 with DAC has been evaluated in controlled human research studies as well as animal models. However, this evidence level should not be interpreted as FDA approval or established therapeutic efficacy.
CJC-1295 with DAC is a modified GHRH(1-29)-derived peptide incorporating amino-acid substitutions that increase enzymatic stability and a Drug Affinity Complex containing a reactive maleimide group. The DAC moiety is designed to form a covalent bond with circulating albumin, substantially extending peptide persistence compared with non-DAC GHRH analogs.
Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys(DAC)-NH₂ Common shorthand: H-Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-(Nε-maleimidopropionyl)Lys-NH₂ This sequence represents the DAC-modified CJC-1295 structure described in structural references for the molecule.
GHRH receptor signaling studies
Growth hormone secretion research
IGF-1 signaling studies
Pituitary-cell research
Albumin-binding peptide research
Long-acting peptide pharmacology
Peptide bioconjugation research
GH pulsatility analysis
Endocrine signaling studies
Pharmacokinetic and pharmacodynamic research
Published research systems involving CJC-1295 include:
GHRH receptor activation models
Rat anterior pituitary systems
GHRH-knockout mouse models
Healthy adult human research subjects
Serum GH and IGF-1 measurement systems
Pharmacokinetic models
Albumin-binding biochemical systems
Pituitary gene-expression models
CJC-1295 has been evaluated in animal and controlled human research, including studies of GH and IGF-1 responses.
HPLC-UV chromatographic purity analysis
LC-MS identity confirmation
Mass-spectrum/reference-spectrum matching
GHRH receptor activation assays
Serum GH assays
Serum IGF-1 assays
Pharmacokinetic analysis
Albumin-binding studies
GH pulsatility analysis
Pituitary GH mRNA analysis
Immunohistochemistry
Endocrine biomarker analysis
The actual OPTMZ product was characterized using HPLC-UV-MS with mass-spectrum/reference-spectrum comparison.
Chromatographic purity
Peptide identity
Peptide content
GHRHR activation
Circulating GH concentration
Circulating IGF-1 concentration
GH pulsatility
Albumin association
Pharmacokinetic persistence
Pituitary GH gene expression
Somatotroph-associated responses
For the actual OPTMZ lot, the directly measured analytical endpoints were chromatographic purity, identity, and net CJC-1295 DAC content.
Independent analytical testing of OPTMZ Peptides CJC-1295 w/DAC 2 mg, lab sample 200513, by Krause Analytical reported:
Chromatographic Purity: 99.63%
CJC-1295 DAC Content: 2.44 mg
Label Claim: 2 mg
Percent of Label: 122.0%
Identity: Confirmed
CAS Number: 446036-97-1
Analysis Method: HPLC-UV-MS
Lab Number: 200513
Project: 145030
Date Received: January 29, 2026
Report Issued: February 9, 2026
The chromatogram and mass-spectrum/reference-spectrum comparison are included on page 2 of the laboratory report.
No endotoxin result is reported on this COA.
Restricted Access · Research Use Only
Independently lab tested, every batch
COAs published and searchable by batch number
Policy version 2026-05-14-ruo-v1.0
Reviews
There are no reviews yet.